We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Leap Therapeutics Inc | NASDAQ:LPTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.63% | 3.19 | 2.37 | 3.29 | 3.28 | 3.01 | 3.27 | 334,593 | 05:00:00 |
From May 2021 to May 2024
By Colin Kellaher
Shares of Leap Therapeutics Inc. rose more than 10% in premarket trading Wednesday after the biotechnology company reported positive data from a Phase 2a study of DKN-01, its most advanced clinical candidate, in combination with BeiGene Ltd.'s tislelizumab.
The Cambridge, Mass., company said the combination showed encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients.
Leap is conducting the study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia and New Zealand.
Leap shares, which closed Tuesday at $2.72, were recently up 11.4% to $3.03 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 19, 2022 07:02 ET (12:02 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Leap Therapeutics Chart |
1 Month Leap Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
